Abstract:Objective To evaluate the clinical curative effect and safety of different doses of calf pulmonary surfactant in the treatment of premature infants with respiratory distress syndrome. Methods The premature infants with respiratory distress syndrome were treated with three different doses of calf pulmonary surfactant. 93 cases met the inclusive criteria among the whole cases. There were 31 cases treated with small doses of calf pulmonary surfac-tant (40-70mg/kg), 31 cases treated with middle doses of calf pulmonary surfactant (70-100 mg/kg) and 31 ca-ses treated with large doses of calf pulmonary surfactant (100-140mg/kg). The results of blood gas analysis were compared among the three groups before and after treatment, including pH, arterial oxygen tension and arterial carbon oxygen tension. Other items of comparison included sex, gestational age, birth weight, cesarean section, Apgar scores, amniotic fluid, need for repeated drug use, need for mechanical ventilation, duration of mechanical ventila-tion, duration of oxygen therapy, duration of hospital stay, outcomes, complications and average hospital expenses. Results There was no significant difference in sex, gestational age, birth weight, cesarean section, Apgar scores, amniotic fluid and premature rupture of membranes among the three groups (P>0. 05). 6 hours after the first appli-cation of pulmonary surfactant, the pH value and the arterial oxygen tension of the whole infants increased in varying degrees, and the arterial carbon oxygen tension of the whole infants decreased in varying degrees ( P<0. 05 ) . The differences of pH value, arterial oxygen tension and arterial carbon oxygen tension among the three groups had no sta-tistical significance before the treatment ( P >0. 05 ) . The difference of the curative effect among the three groups ( including the need for repeated drug use, the need for mechanical ventilation, the duration of mechanical ventilation and the duration of oxygen therapy) had no statistical significance (P>0. 05). There was no significant difference in complication morbidity and the cure rate among the three groups (P>0. 05), but it showed significant differences in the average hospital expenses and the average duration of hospital stay among the three groups ( P<0. 05 ) . Com-pared with the large dose group, the average hospital expenses in the middle dose group decreased. And compared with the small dose group, the average duration of hospital stay in the middle dose group decreased. Conclusion The clinical curative effect and safety of the three doses of calf pulmonary surfactant are analogous in the treatment of premature infants with respiratory distress syndrome. But the average hospitalization expenses in the middle doses group is less than that of the large doses groups, and the average duration of hospitalization in the middle dose group is less than that of the small doses group.

Beneficial Effect of Exogenous Surfactant in Infants Suffering Acute Respiratory Distress Syndrome after Cardiac Surgery.

Beneficial effect of exogenous pulmonary surfactant in infants suffering acute respiratory distress syndrome after cardiac surgery

Effect of low-dose exogenous surfactant on infants with acute respiratory distress syndrome after cardiac surgery: a retrospective analysis

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

Administration of exogenous pulmonary surfactant after cardiac surgery in infants

Analysis of the effectiveness of pulmonary surfactant in the treatment of moderate and severe acute respiratory distress syndrome in infants and toddlers —a multicenter prospective study

Effect of High-Frequency Oscillatory Ventilation Combined With Pulmonary Surfactant in the Treatment of Acute Respiratory Distress Syndrome After Cardiac Surgery: A Prospective Randomised Controlled Trial

The impact of surfactant replacement therapy on cerebral and systemic circulation and lung function

Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome

Modified Protocols for Surfactant Therapy in Experimental Meconium Aspiration Syndrome

Effect of Surfactant Administration on Outcomes of Adult Patients in Acute Respiratory Distress Syndrome: a Meta-Analysis of Randomized Controlled Trials

Observation on the Clinical Curative Effect of Different Doses of Calf Pulmonary Surfactant in the Treatment of Premature Infants with Respiratory Distress Syndrome

Therapeutic effects of inhaling aerosolized surfactant alone or with dexamethasone generated by a novel noninvasive apparatus on acute lung injury in rats.

Exogenous surfactant for lung contusion causing ARDS: A systematic review of clinical and experimental reports

Rescue Treatment of Neonatal Respiratory Distress Syndrome

Effects of Pulmonary Surfactant in Adult Patients with Acute Lung Injury/Acute Respiratory Distress Syndrome:A Meta-analysis

Comparison of the effect of Calsurf and Curosurf in treating respiratory distress syndrome of preterm infants

Aerosolized Surfactant and Dextran for Experimental Acute Respiratory Distress Syndrome Caused by Acidified Milk in Rats

Gender-related Efficacy of Pulmonary Surfactant in Infants with Respiratory Distress Syndrome: A STROBE Compliant Study

The Oberservation of Effect of Pulmonary Surfactant on Preterm Infant's Respiratory Distress Syndrome

Surfactant Reduced the Mortality of Neonates with Birth Weight ⩾1500 G and Hypoxemic Respiratory Failure: a Survey from an Emerging NICU Network